Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

61. Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. Randomized clinical trials of vitamin D supplementation for secondary prevention in patients with cancer are needed, given positive results of observational studies.To determine whether postoperative vitamin D3 supplementation can improve survival of patients with digestive tract cancers overall and in subgroups stratified by 25-hydroxyvitamin D (25 (...) [OH]D) levels.The AMATERASU trial, a randomized, double-blind, placebo-controlled trial conducted at a single university hospital in Japan. Enrollment began in January 2010 and follow-up was completed in February 2018. Patients aged 30 to 90 years with cancers of the digestive tract from the esophagus to the rectum, stages I to III, were recruited. Of 439 eligible patients, 15 declined and 7 were excluded after operation.Patients were randomized to receive oral supplemental capsules of vitamin D

2019 JAMA Controlled trial quality: predicted high

62. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer (...) Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why

2019 European Medicines Agency - EPARs

63. Early Detection for Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

Early Detection for Colorectal Cancer Resource-Stratified Guideline Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00213 Journal of Global Oncology - published online before print February 25, 2019 PMID: Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline , MD, MBA 1 (...) Lumpur, Malaysia 10 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 11 Shahid Beheshti University, Tehran, Iran 12 Columbia Asia Hospitals, Bangalore, India, and Weill Cornell Medical College, New York, NY 13 New York-Presbyterian/Weill Cornell Medical Center, New York, NY 14 Makati Medical Center, Makati, Philippines 15 Homerton University Hospital Foundation Trust, Bowel Disease Research Foundation, London, United Kingdom 16 The University of Puerto Rico

2019 American Society of Clinical Oncology Guidelines

64. Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline | Journal of Global Oncology Search in: Menu Article Tools SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JGO.18.00214 Journal of Global Oncology - published online before print February 25, 2019 PMID: Treatment of Patients With Early-Stage (...) Colorectal Cancer: ASCO Resource-Stratified Guideline , MD, MPH 1 x Ainhoa Costas-Chavarri ; , MD 2 3 x Govind Nandakumar ; , MSPH 4 x Sarah Temin ; , MD, MBA 5 x Gilberto Lopes ; , MD, PhD 6 x Andres Cervantes ; , MD, PhD 7 8 x Marcia Cruz Correa ; , MD 9 x Rena Engineer ; , MD, PhD 10 x Chisato Hamashima ; , MD 11 x Gwo Fuang Ho ; , MD 12 x Fidel David Huitzil ; , MD 13 x Mona Malekzadeh Moghani ; , MD 14 x Ala I. Sharara ; , PhD 15 x Mariana C. Stern ; , MD 16 x Catherine Teh ; , MD 12 x Sara E

2019 American Society of Clinical Oncology Guidelines

65. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer (Abstract)

Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer MINI: In the present study, we systemically and comprehensively evaluated the prognostic significance of a combination of inflammatory factors using preoperative blood examination, and focused on the potential feasibility of our newly developed lymphocyte-CRP ratio (LCR) as a prognostic biomarker in CRC patients. We have firstly identified that a combination (...) of lymphocytic counts along with CRP levels, which we defined as LCR, is a more reliable indicator of poor prognosis compared with other combinations of inflammatory markers, in CRC patients. Furthermore, preoperative LCR could also identify CRC patients who are at higher risk for postoperative infectious complications.Systemic inflammation via host-tumor interactions is currently recognized as a hallmark of cancer. The aim of this study was to evaluate the prognostic value of various combinations

2019 EvidenceUpdates

66. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study (Abstract)

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while maintaining health-related quality of life (HRQOL) in patients who undergo resection.We

2019 EvidenceUpdates

67. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial) (Abstract)

in a multicentre, open-label RCT in six centres in the Netherlands. Patients with colorectal cancer scheduled for elective curative surgery with a primary anastomosis were eligible. Oral colistin, tobramycin and amphotericin B were administered to patients in the SDD group to decontaminate the digestive tract. Both treatment and control group received intravenous cefazolin and metronidazole for perioperative prophylaxis. Mechanical bowel preparation was given for left-sided colectomies, sigmoid and anterior (...) Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial) Infectious complications and anastomotic leakage affect approximately 30 per cent of patients after colorectal cancer surgery. The aim of this multicentre randomized trial was to investigate whether selective decontamination of the digestive tract (SDD) reduces these complications of elective colorectal cancer surgery.The effectiveness of SDD was evaluated

2019 EvidenceUpdates

68. Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests (Abstract)

Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests The impact of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening on disease incidence and mortality is affected by participation, which might be influenced by ease of use of the FIT. We compared the participation rates and ease of use of 2 different FITs in a CRC screening program.There were two study designs within the Dutch CRC screening program. In a paired cohort

2019 EvidenceUpdates

69. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) daily. • There is no recommendation for or against aspirin therapy in adults aged < 50 or = 60 years. • Exclude adults with increased risk of bleeding. This includes those with a history of gastrointestinal (GI) bleeding, GI ulcers, intracranial bleed, bleeding disorders, renal failure, severe liver disease, thrombocytopenia, or using NSAIDS daily, or other medicine to prevent blood clots. The recommendations above reflect a change from initiate to consider in adults aged 50-59 years with 10-year

2019 Kaiser Permanente National Guideline Program

70. Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. Full Text available with Trip Pro

Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. To explore the risk of colorectal cancer in family members of patients with colorectal cancer, with an emphasis on subtypes of second degree relatives, especially half siblings, which were lacking in the literature.Ambidirectional cohort study.Nationwide Swedish Family Cancer Data (record linkage).All people residing in Sweden and born after 1931, with their biological parents, totalling >16 million (...) individuals (follow-up: 1958-2015); of those with clear genealogy, 173 796 developed colorectal cancer.Lifetime (0-79 years) cumulative risk and standardised incidence ratio of colorectal cancer among first degree relatives and second degree relatives.The overall lifetime cumulative risk of colorectal cancer in siblings of patients was 7%, which represents a 1.7-fold (95% confidence interval 1.6 to 1.7; n=2089) increase over the risk in those without any family history of colorectal cancer. A similarly

2019 BMJ

71. Screening for colorectal cancer-where does the fit-DNA test fit?

Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(23):2564-2575. . Centers for Disease Control and Prevention. National Health Interview Survey. Available at: . Published March 1, 2014. Accessed June 21, 2018. .National Cancer Institute. SEER Cancer Statistics Fact sheets: Colon and Rectum Cancer. Available at: .Published September, 2014. Accessed June 21, 2018 (...) will continue to improve, and blood tests for CRC are in development. Research and one blood test, Epi pro Colon, was approved by the FDA in 2016. However, it is not currently recommended by the USPSTF. As this area of research develops, it is important that physicians remain aware of all the currently available USPTSF-approved screening modalities. “One size fits all” may not be the most effective cancer screening approach for all patients. Studies have shown that colonoscopy may be avoided by large

2019 Clinical Correlations

72. Clinical Utility Card - Heritable mutations which increase risk in colorectal and endometrial cancer

, SMAD4, BMPR1A, MLH1, MSH2, MSH6, PMS2, STK11, GREM1, MUTYH, and EPCAM* [*deletions associated with epigenetic silencing of MSH2]. Generally for the gastrointestinal (GI) cancer predisposition genes, those testing positive require close surveillance with colonoscopy to detect the rapidly growing cancers which occur driven by, for example, the mutator phenotype (accumulating hundreds of mutations in the tumours) typically of Lynch Syndrome. Those who do develop colorectal cancer are usually advised (...) this rearrangement. 3. Summary of consideration and rationale for MSAC’s advice MSAC noted that the proposed purposes and populations are (a) diagnostic testing of patients with either (i) colorectal or endometrial carcinoma and features suggestive of a hereditary basis, or (ii) a colonic polyposis syndrome, plus (b) cascade testing of relatives of those individuals who are diagnosed with the relevant germline gene variants. The diagnostic genetic test is to characterise germline gene variants in three or more

2019 Medical Services Advisory Committee

73. Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain Full Text available with Trip Pro

Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain The aim of the study was to measure the effect of three cost-neutral behavioral interventions on participation compared to the standard invitation letter in a population-based colorectal cancer screening program in 2014. For that purpose, a four-arm randomized field trial was conducted among 5077 individuals aged 50 to 69 years. Over an 8-week period, each (...) participation (OR: 0.60; 95% CI: 0.38-0.95). While none of the intervention strategies improved participation rates we found that praising the benefit of regular screening may discourage individuals who have never been invited before as the continuous behavior may be perceived as a large request. Nevertheless, the reminder letter boosted participation rates independently of the intervention assigned.Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.

2019 EvidenceUpdates

74. Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in Colorectal Cancer. (Abstract)

Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in Colorectal Cancer. Considering the relation between preoperative functional capacity and postoperative complications, enhancing patients' functional capacity before surgery with a prehabilitation program may facilitate faster recovery and improve quality of life. However, time before surgery is short, mandating a multimodal and high-intensity training approach. This study investigated feasibility (...) for colorectal cancer patients is feasible, safe, and effective. A randomized controlled trial (NTR5947) was initiated to determine whether prehabilitation may lower morbidity and mortality rates in colorectal surgery.

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

75. Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. Full Text available with Trip Pro

Adjuvant Chemotherapy of Locally Advanced Colon Cancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. There is still the need to optimize adjuvant treatment of colon cancer (CC). Standard adjuvant chemotherapy using 5-fluorouracil (FU) and folinic acid (FA) was compared with a combination including irinotecan (Folfiri). The aim of the present report was to analyze overall survival (OS) after long-term follow-up, to summarize final recurrence rates (...) in 17 (12.8%) patients treated with FUFA and in 50 (36.8%) patients treated with Folfiri. Recurrences occurred in 46 of 133 (34.6%) and in 47 of 136 (34.6%) patients who received FUFA and Folfiri, respectively. 5-year OS rates were 69.9% (95% confidence interval (CI): 61.2-77.1) for FUFA and 72.7% (95% CI: 63.9-79.8) for Folfiri. OS was associated with tumor grading (1 & 2 vs. 3), tumor sub-stage (II vs. IIIa vs. IIIb vs. IIIc), and tumor location (left vs. right colon).Folfiri cannot be generally

2019 Visceral medicine Controlled trial quality: uncertain

76. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) Full Text available with Trip Pro

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine (...) of 421 randomly assigned patients (arm A: n = 212; arm B: n = 209) formed the full analysis set. Median age was 71 and 69 years, respectively. Noninferiority of TFS was not shown (hazard ratio [HR], 0.86; 90% CI, 0.73 to 1.02). In detail, patients with RAS/BRAF wild-type tumors benefitted from combination chemotherapy (HR, 0.61; 90% CI, 0.46 to 0.82; P = .005), whereas patients with RAS mutant tumors (HR, 1.09; 90% CI, 0.81 to 1.46; P = .58) did not (Cox model for interaction of study arm and RAS

2019 EvidenceUpdates

77. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial Full Text available with Trip Pro

Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screenings for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs (...) diagnosed with CRC 30 days or longer after screening (interval cancer group, n = 163) and individuals diagnosed with CRC in the nonscreened group (controls, n = 1740). All CRCs in the control group were identified when they developed symptoms (clinically detected CRCs). Analyses were stratified by cancer site. We used Cox regression to estimate hazard ratio (HRs), adjusted for age and sex.Over the follow-up period, 43 individuals in the interval cancer group died from CRC; among controls, 525 died from

2019 EvidenceUpdates

78. Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer

Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectal cancer or at increased risk of colorectal cancer Advice for NHSScotland Colon capsule endoscopy (CCE-2 (...) ) is not recommended for routine use in NHSScotland for the detection of colorectal polyps and cancer. The clinical effectiveness evidence is currently limited, no relevant published evidence on the cost effectiveness of the technology was identified, and its place in the patient care pathway has still to be established. CCE-2 may however be considered as an additional testing option in patients who are able to undergo the intensive bowel cleansing needed for CCE-2 and who have contraindications for optical

2019 Evidence Notes from Healthcare Improvement Scotland

79. Screening for Colorectal Cancer

with papillary thyroid cancer that is the cribriform-morular variant, or hepatoblastoma Individuals with a diagnosis of CRC and>10 colorectal adenomas Individuals with a personal history of20 adenomas Individuals with multiple gastrointestinal hamartomatous polyps or serrated polyposis syndrome Individuals from a family with a known hereditary syndrome associated with CRC with or without a known mutation Individuals with a desmoid tumor, multifocal or bilateral CHRPE CHRPE, congenital hypertrophy of retinal (...) of CRC or advanced adenoma warrants more intense screening for CRC. Well-designed prospective studies are needed in order to make de?nitive evidence-based recommendations about the age to commence screening and appropriate interval between screening tests. Keywords: Adenoma; Cancer; Colonoscopy; Colorectal; FOBT; Neoplasms; Polyp; Screening. Executive Summary Colorectal cancer (CRC) is the second leading cause of cancer deaths in Canada and the United States. A positive family history (FH) signi

2018 Canadian Association of Gastroenterology

80. Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342)

) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectal cancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping (...) . Perspective: These studies emphasize the extra-intestinal manifestations of colorectal cancer. The dental anomalies, commonly considered incidental findings, appear around 10 years before the clinical evidence of the intestinal polyps and the dental professional should be aware of these correlations. Since the gene mutation affects families, it is important to early detect, refer and map genetically these patients reducing the morbidity. The colorectal cancer is considered a public health issue, FAP

2018 UTHSCSA Dental School CAT Library